Focus ultrasound (FUS) has the potential to revolutionise therapy to the same degree that magnetic resonance imaging (MRI) ...

Field medical education before launch is linked to greater launch success, improving treatment adoption by up to 50%. New ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care ...

Watertown, Massachusetts-based Disc has agreed with the FDA that it will use average monthly time in sunlight during the last ...

CRUK has invested more than £43 million into the RadNet programme since it was launched in 2019, and Manchester is one of ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

With a mix of breakout sessions, hands-on workshops, and in-depth discussions, learning from real-world case studies that ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing staff to speed up ...